Ethyl 3-[[1-(2-ethoxy-2-oxoethyl)cyclopropyl]amino]-3-oxopropanoate | 1265017-65-9

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: Ethyl 3-[[1-(2-ethoxy-2-oxoethyl)cyclopropyl]amino]-3-oxopropanoate
• CAS: 1265017-65-9
• 化学式: C₁₂H₁₉NO₅
• 分子量: 257.287
• InChiKey: IJHMKSAWLAXQPH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  18
• 可旋转键数：
  9
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  81.7
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  Ethyl 3-[[1-(2-ethoxy-2-oxoethyl)cyclopropyl]amino]-3-oxopropanoate 在 sodium methylate 作用下， 以 甲苯 为溶剂， 反应 0.75h， 生成 ethyl 5,7-dioxo-4-azaspiro[2.5]octane-6-carboxylate
  参考文献：
  名称：

  In vivo and in vitro SAR of tetracyclic MAPKAP-K2 (MK2) inhibitors. Part II

  摘要：

  Spirocyclopropane- and spiroazetidine-substituted tetracycles 13D-E and 16A are described as orally active MK2 inhibitors. The spiroazetidine derivatives are potent MK2 inhibitors with IC(50) <3 nM and inhibit the release of TNF alpha (IC(50)<0.3 mu M) from hPBMCs and hsp27 phosphorylation in anisomycin stimulated THP-1 cells. The spirocyclopropane analogues are less potent against MK2 (IC(50) = 0.05-0.23 mu M), less potent in cells (IC(50)<1.1 mu M), but show good oral absorption. Compound 13E (100 mg/kg po; bid) showed oral activity in rAIA and mCIA, with significant reduction of swelling and histological score. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.04.023
• 作为产物：
  描述：

  2-(1-氨基环丙基)乙酸乙酯 、 氯甲酰乙酸乙酯 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 0.5h， 生成 Ethyl 3-[[1-(2-ethoxy-2-oxoethyl)cyclopropyl]amino]-3-oxopropanoate
  参考文献：
  名称：

  In vivo and in vitro SAR of tetracyclic MAPKAP-K2 (MK2) inhibitors. Part II

  摘要：

  Spirocyclopropane- and spiroazetidine-substituted tetracycles 13D-E and 16A are described as orally active MK2 inhibitors. The spiroazetidine derivatives are potent MK2 inhibitors with IC(50) <3 nM and inhibit the release of TNF alpha (IC(50)<0.3 mu M) from hPBMCs and hsp27 phosphorylation in anisomycin stimulated THP-1 cells. The spirocyclopropane analogues are less potent against MK2 (IC(50) = 0.05-0.23 mu M), less potent in cells (IC(50)<1.1 mu M), but show good oral absorption. Compound 13E (100 mg/kg po; bid) showed oral activity in rAIA and mCIA, with significant reduction of swelling and histological score. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.04.023

文献信息

• [EN] USE OF CONDENSED BENZO[B]THIAZINE DERIVATIVES AS CYTOPROTECTANTS<br/>[FR] UTILISATION DE DÉRIVÉS DE BENZO[B]THIAZINE EN TANT QU'AGENTS CYTOPROTECTEURS
  申请人：MEDEIA THERAPEUTICS LTD

  公开号：WO2014191632A1

  公开（公告）日：2014-12-04

  The present invention relates to arylthiazine compounds, metabolites, N-oxides, amides, esters,pharmaceutically acceptable salts, hydrates and solvates thereof and their use as cytoprotectants in the treatment or prophylaxis of diseases or states, either acute or chronic, involving aberrant cellular lipid peroxidation in the central nervous system or in the periphery of the body. The present invention also relates to a method for their preparation and to pharmaceutical composition comprising as an active ingredient one or more of the aforementioned compounds.

  本发明涉及芳基噻嗪化合物、代谢物、N-氧化物、酰胺、酯、药用可接受盐、水合物和溶剂合物，以及它们在治疗或预防涉及中枢神经系统或身体周围存在异常细胞脂质过氧化的疾病或状态中作为细胞保护剂的用途。本发明还涉及它们的制备方法以及包含作为活性成分的上述化合物之一或多个的药物组合物。
• USE OF CONDENSED BENZO[B]THIAZINE DERIVATIVES AS CYTOPROTECTANTS
  申请人：ARANDA PHARMA LTD

  公开号：US20160106754A1

  公开（公告）日：2016-04-21

  The present invention relates to arylthiazine compounds, metabolites, N-oxides, amides, esters,pharmaceutically acceptable salts, hydrates and solvates thereof and their use as cytoprotectants in the treatment or prophylaxis of diseases or states, either acute or chronic, involving aberrant cellular lipid peroxidation in the central nervous system or in the periphery of the body. The present invention also relates to a method for their preparation and to pharmaceutical composition comprising as an active ingredient one or more of the aforementioned compounds.

  本发明涉及芳基噻嗪化合物、代谢物、N-氧化物、酰胺、酯、药学上可接受的盐、水合物和溶剂化物，以及它们在治疗或预防涉及中枢神经系统或身体周围的异常细胞脂质过氧化的急性或慢性疾病或状态中作为细胞保护剂的用途。本发明还涉及一种它们的制备方法和包含上述化合物中的一个或多个作为活性成分的制药组合物。
• US9827249B2
  申请人：——

  公开号：US9827249B2

  公开（公告）日：2017-11-28